AstraZeneca
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after the company report...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufa...
Latest News
23 hours ago · fool.com
AstraZeneca: 3 Key Takeaways for Long-Term InvestorsTotal revenue grew 7% across the first nine months of 2026. AstraZeneca launched a $2 billion restructuring initiative through 2029.
2 days ago · seekingalpha.com
AstraZeneca PLC (AZN) Q3 2026 Earnings Call TranscriptAstraZeneca PLC (AZN) Q3 2026 Earnings Call Transcript
2 days ago · marketbeat.com
AstraZeneca Q3 Earnings Call HighlightsAstraZeneca NYSE: AZN reported continued revenue and earnings growth for the first nine months of 2026, supported by double-digit expansion in oncology, rare disease and respiratory and immunology, while loss-of-exclusivity pressures weighed on parts of its cardiovascular, renal and metabolism portfolio.
2 days ago · zacks.com
AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales GrowthAstraZeneca beats Q3 earnings and revenue estimates as oncology sales surge 17%, offsetting generic pressure on mature drugs.
2 days ago · zacks.com
Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesAlthough the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
2 days ago · youtube.com
AstraZeneca CFO on AI, Earnings, Restructuring PlanAstraZeneca Chief Financial Officer Aradhana Sarin says the drug company uses AI in almost every aspect of the work they do. She talks beating on earnings, their drug pipeline and how the company approaches dealmaking.
2 days ago · barrons.com
AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling StockAstraZeneca aims to free up funds to reinvest into its pipeline and meet its goal of $80 billion in annual revenue by 2030.
3 days ago · businesswire.com
AstraZeneca results: 9M and Q3 2026CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary 9M 2026 % Change Q3 2026 % Change $m Actual CER1 $m Actual CER - Product Sales 43,962 7 5 15,066 5 5 - Alliance Revenue 2,806 33 32 1,107 36 36 Product Revenue 46,768 8 6 16,173 7 7 Collaboration Revenue 113 22 23 36 >3x >3x Total Revenue 46,881 8 7 16,209 7 7 Reported EPS ($) 5.62 10 11 2.02 23 26 Core2 EPS ($) 8.00 14 14 2.79 17 19 Key performance elements for 9M 2026 (Growth numbers at constant exchange rates.
3 days ago · reuters.com
FTSE 100 set for monthly gains; AstraZeneca up after resultsLondon's FTSE 100 looked on track to log its first monthly gain in three months, edging up on Friday as AstraZeneca rose, with investors welcoming a budget that was softer than expected on taxes.
3 days ago · wsj.com
AstraZeneca Posts Revenue, Profit Growth on Strong Cancer-Drug SalesThe U.K. drugmaker reported net profit of $3.12 billion for the third quarter, up from $2.535 billion for the same period last year.
Earnings
Add to Watchlist
Select watchlists to add or remove AZN